July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Comparison of eplerenone versus melatonin as therapeutic options for the treatment of non-resolving and chronic central serous chorioretinopathy
Author Affiliations & Notes
  • Tomas Nabil Saddi
    Retina, Centro privado de ojos romagosa, Cordoba, Cordoba, Argentina
  • Juan Pablo Real
    Unidad de Investigación y Desarrollo en Tecnología Farmacéutica - CONICET, Cordoba, Cordoba, Argentina
    Departamento de Farmacia, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Cordoba, Cordoba, Argentina
  • Eleonora Lavaque
    Retina, Hospital oftalmológico Santa Lucía, Buenos Aires, Buenos Aires, Argentina
  • Ana Laura Gramajo
    Retina, Centro privado de ojos romagosa, Cordoba, Cordoba, Argentina
  • Claudio Patricio Juarez
    Retina, Centro privado de ojos romagosa, Cordoba, Cordoba, Argentina
  • Ruth Estela Rosenstein
    Centro de Estudios Farmacologico y Botanicos, Buenos Aires, Buenos Aires, Argentina
    Retina and vitreous, Centro privado de ojos, Mar del plata, Buenos Aires, Argentina
  • Jose D Luna Pinto
    Retina, Centro privado de ojos romagosa, Cordoba, Cordoba, Argentina
  • Footnotes
    Commercial Relationships   Tomas Saddi, None; Juan Real, None; Eleonora Lavaque, None; Ana Gramajo, None; Claudio Juarez, None; Ruth Rosenstein, None; Jose Luna Pinto, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4078. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tomas Nabil Saddi, Juan Pablo Real, Eleonora Lavaque, Ana Laura Gramajo, Claudio Patricio Juarez, Ruth Estela Rosenstein, Jose D Luna Pinto; Comparison of eplerenone versus melatonin as therapeutic options for the treatment of non-resolving and chronic central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4078. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : At present, there are no optimal therapies for chronic CSCR (central serous chorioretinopathy). Eplerenone and melatonin are two of the many therapeutic option described for this systemic disease. The aim of this study is to compare the efficacy of melatonin and eplerenone for CSCR treatment.

Methods : A comparative, retrospective study was developed with 36 patients with chronic CSCR. Twenty patients were treated with 50 mg/day of oral eplerenone for 3 months and 16 patients were treated orally with 3 mg melatonin three times a day for 1 month. Most of the patients had previous failed treatments for their condition. Observational procedures included ETDRS best-corrected visual acuity (BCVA), complete ophthalmic examination and Optical Coherence Tomography. Four time points were used: baseline, 1, 3 and 6 months.

Results : At one month follow up, CMT (central macular thickness) showed a significant decrease (p< 0.005) on both treatment groups, but change in macular thickness was significantly lower in the eplerenone group (p<0.05 at 1, 3 and 6 months). The mean decreased on CMT at 6 month was -44.9 µm and -218.2 µm for the eplerenone and melatonin groups respectively. In terms of BCVA, both treatment groups showed a mean significant improvement on visual acuity with a little differences in favor of melatonin treatment. No significant side effects were observed in any of the treatment groups.

Conclusions : Both eplerenone and melatonin are effective treatments for patients with CSCR, although there are small clinical differences in favor of melatonin when both treatments are compared.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

Change in Best Corrected Visual Acuity (BCVA)

Change in Best Corrected Visual Acuity (BCVA)

 

Change in Central Macular Thickness (CMT)

Change in Central Macular Thickness (CMT)

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×